Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Investigational Drug Branch (IDB)

About IDB

Dr. Steven Gore

Dr. Steven Gore is CTEP's Investigational Drug Branch Chief.

The Investigational Drug Branch manages NCI's innovative early phase experimental therapeutics program, which has contributed to the clinical development of anticancer agents since the early 1970s.  Through this program, hundreds of agents, both small molecule and immunologic, have been made available for collaborative development.

IDB has scientific oversight of the NCI's Experimental Therapeutics Clinical Trials Network (ETCTN), which performs clinical studies of promising anti-cancer agents in collaboration with the academic and pharmaceutical industry research communities.

Read more about CTEP's end-to-end support for novel anti-cancer agent development.

IDB physicians work with ETCTN investigators and industry partners to drive the clinical development of NCI-IND agents, including:

  • Reviewing and prioritizing clinical trial proposals
  • Monitoring ETCTN clinical trials for safety and efficacy
  • Investigating and preparing reports concerning adverse events (AEs) for the NCI-IND agents
  • Working closely with the Investigational Drug Steering Committee to increase the transparency and openness of the trial design and prioritization process.

ETCTN investigators can learn more about designing and submitting a Letter of Intent (LOI) on our Trial Development Resources page or find the IDB drug monitor for a particular agent by reviewing the list of Agents Available Under CTEP CRADAs.

CTEP IDB Staff Directory

NameRoleEmail Address
Steven Gore, M.D.Branch Chiefsteven.gore@nih.gov
Helen X. Chen, M.D.Associate Branch Chief (Immunooncology)helen.chen@nih.gov
Andrecia Cunningham, M.S., B.S.N.Clinical Operations Managerandrecia.cunningham@nih.gov
Brian Ko, M.D.Medical Officer (Immunooncology)brian.ko@nih.gov
Lorraine Pelosof, M.D., Ph.D.Medical Officer (Small molecules, epigenetics)lorraine.pelosof@nih.gov
Cheryl Pickett-Gies, M.D., Ph.D.Medical Officer (Immunooncology)cheryl.pickett@nih.gov
Nicole PultarAdministrative Assistantnicole.pultar@nih.gov
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Investigational Drug Branch (IDB) was originally published by the National Cancer Institute.”

Email